ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Jupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS)

0.680399
0.0604
( 9.74% )
업데이트: 02:36:54

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.680399
매수가
0.68
매도가
0.7199
거래량
321,195
0.613 일간 변동폭 0.77
0.55 52주 범위 19.51
market_cap
전일 종가
0.62
개장가
0.638
최근 거래 시간
29
@
0.7111
마지막 거래 시간
02:42:18
재정 규모
US$ 221,777
VWAP
0.690475
평균 볼륨(3m)
528,065
발행 주식
33,103,860
배당수익률
-
주가수익률
-4.71
주당순이익(EPS)
-0.14
매출
-
순이익
-4.78M

Jupiter Neurosciences Inc 정보

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we pri... Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL¿ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
본부
Wilmington, Delaware, USA
설립됨
-
Jupiter Neurosciences Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker JUNS. The last closing price for Jupiter Neurosciences was US$0.62. Over the last year, Jupiter Neurosciences shares have traded in a share price range of US$ 0.55 to US$ 19.51.

Jupiter Neurosciences currently has 33,103,860 shares in issue. The market capitalisation of Jupiter Neurosciences is US$20.52 million. Jupiter Neurosciences has a price to earnings ratio (PE ratio) of -4.71.

JUNS 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.09049915.34141379890.58990.770.5601542540.62126987CS
4-0.160601-19.09643281810.8410.8648990.551199370.66518055CS
12-11.199601-94.272735690211.8812.50.555280653.53531393CS
26-3.319601-82.990025419.510.555185574.92784853CS
52-3.319601-82.990025419.510.555185574.92784853CS
156-3.319601-82.990025419.510.555185574.92784853CS
260-3.319601-82.990025419.510.555185574.92784853CS

JUNS - Frequently Asked Questions (FAQ)

What is the current Jupiter Neurosciences share price?
The current share price of Jupiter Neurosciences is US$ 0.680399
How many Jupiter Neurosciences shares are in issue?
Jupiter Neurosciences has 33,103,860 shares in issue
What is the market cap of Jupiter Neurosciences?
The market capitalisation of Jupiter Neurosciences is USD 20.52M
What is the 1 year trading range for Jupiter Neurosciences share price?
Jupiter Neurosciences has traded in the range of US$ 0.55 to US$ 19.51 during the past year
What is the PE ratio of Jupiter Neurosciences?
The price to earnings ratio of Jupiter Neurosciences is -4.71
What is the reporting currency for Jupiter Neurosciences?
Jupiter Neurosciences reports financial results in USD
What is the latest annual profit for Jupiter Neurosciences?
The latest annual profit of Jupiter Neurosciences is USD -4.78M
What is the registered address of Jupiter Neurosciences?
The registered address for Jupiter Neurosciences is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Jupiter Neurosciences website address?
The website address for Jupiter Neurosciences is www.jupiterneurosciences.com
Which industry sector does Jupiter Neurosciences operate in?
Jupiter Neurosciences operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PSTVPlus Therapeutics Inc
US$ 1.47
(187.67%)
238M
SAGSAG Holdings Ltd
US$ 1.14
(68.89%)
116.89M
OPTNOptiNose Inc
US$ 9.20
(53.33%)
1.56M
AEVAAeva Technologies Inc
US$ 4.21
(35.37%)
3.82M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 244.76
(34.19%)
415
ELEVElevation Oncology Inc
US$ 0.2924
(-38.80%)
13.47M
BHILBenson Hill Inc
US$ 0.4378
(-32.17%)
1.2M
LSELeishen Energy Holding Company Ltd
US$ 8.63
(-30.96%)
528.65k
ADAPAdaptimmune Therapeutics PLC
US$ 0.3136
(-30.17%)
11.77M
XHLDTEN Holdings Inc
US$ 1.115
(-29.87%)
13.23M
PSTVPlus Therapeutics Inc
US$ 1.47
(187.67%)
238M
NVDANVIDIA Corporation
US$ 118.1245
(0.51%)
156.53M
AGMHAGM Group Holdings Inc
US$ 0.077799
(8.05%)
146.61M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.0976
(-0.52%)
117.36M
SAGSAG Holdings Ltd
US$ 1.14
(68.89%)
116.89M

JUNS Discussion

게시물 보기
swingingRichard swingingRichard 2 주 전
JUNS is running a promotion. Currently being touted by "RedChip" on Bloomberg TV. 
👍️0
tw0122 tw0122 3 월 전
Back down to $11 halt 38% 
👍️0
Invest-in-America Invest-in-America 3 월 전
JUNS: WHERE do you see that 120%??? Is that your price TARGET??? (Etrade, etc.,.shows only 38%.)
👍️0
tw0122 tw0122 3 월 전
$17 +120%
👍️0
Invest-in-America Invest-in-America 3 월 전
JUNS: O.K., sounds fine to me, Homeboy!!
👍️0
tw0122 tw0122 3 월 전
From Saturn off to Jupiter $11.79 + 50%
👍️0
Invest-in-America Invest-in-America 3 년 전
JUNS (IPO):
👍️0
makinezmoney makinezmoney 3 년 전
$JUNS: IPO is launching next week

We are waiting on it.



Jupiter Neurosciences, Inc. has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.

https://jupiterneurosciences.com/








GO $JUNS
👍️0
Invest-in-America Invest-in-America 3 년 전
JUNS: Evidently, now ready-to-go on E-Turd, Fidelity, etc.
👍️0
spindog spindog 3 년 전
Ticker hasn’t shown up on E*TRADE yet
👍️0
crudeoil24 crudeoil24 3 년 전
IPO scheduled for February 3, 2022.
👍️0
crudeoil24 crudeoil24 3 년 전
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
👍️0